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OBJECTIVES This study was designed to determine whether patient characteristics collected at presentation
can identify which patients benefit from immediate coronary angiography and revasculariza-
tion.
BACKGROUND Risk stratification may offer a method for identifying which patients with unstable angina or
non–Q-wave myocardial infarction (NQMI) are likeliest to benefit from invasive manage-
ment strategies.
METHODS The analysis was based on data from a randomized controlled trial that enrolled 1,473 patients
presenting with unstable angina or NQMI who were randomly assigned to an early invasive
or early conservative (medical) management strategy. We constructed a risk-stratification
score for each patient based on adjusted odds ratios for clinical variables likely to predict
adverse outcomes. We stratified all trial subjects by their risk scores and studied the rates of
death or myocardial infarction (MI) of the early invasive management strategy in each
stratum.
RESULTS The final multivariate model included older age, ST segment depression on presentation,
history of complicated angina before presentation, and elevation in baseline creatine
kinase-MB fraction. Although patients with a higher risk score had an increased rate of death
or MI within 42 days and 365 days (p , 0.001) in both management strategies, early invasive
management for patients in the high and very high risk categories was associated with a lower
rate of death or MI within 42 days compared with conservative management. No such benefit
was seen in patients in the larger group of patients in the very low, low or moderate risk
categories (p 5 0.03 for the interaction between risk category and management assignment).
CONCLUSIONS Risk stratification may be an effective method for identifying those patients with unstable
angina or NQMI most likely to benefit from early invasive management. Selective use of early
invasive management can have a substantial impact in reducing morbidity and mortality in
higher risk patients, but may not be warranted in lower risk patients. (J Am Coll Cardiol
2001;38:969–76) © 2001 by the American College of Cardiology
While the management of unstable angina rapidly evolves, it
remains important to identify which patients require routine
early coronary angiography and revascularization if indi-
cated, versus more conservative management. At least three
See page 977
published studies have examined the efficacy of early cath-
eterization for unstable angina or non–Q-wave myocardial
infarction (NQMI) (1–3). In unselected patients enrolled in
current trials, this approach has failed to show a morbidity
or mortality benefit over medical management (1,2). A
European trial did find an advantage with an early invasive
strategy; patients in this study were required to have
electrocardiographic changes or cardiac enzyme abnormal-
ities upon presentation, so that population may not reflect
the broader spectrum of patients presenting with unstable
angina or NQMI (3). Furthermore, the invasive strategy in
that trial cannot be considered “early” because it was
implemented up to three days after treatment with heparin
or low-molecular-weight heparin. Another recent study
suggests that an early invasive strategy may be useful in
patients with unstable angina who have received a glycop-
rotein (Gp) IIb/IIIa agent (4).
The inconsistent findings of these large clinical trials
might be explained by different enrollment criteria or
treatment protocols; another possibility is that the popula-
tions for each trial differed in baseline risk factor profiles.
Not all patients with unstable angina or NQMI are at equal
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risk for cardiac events. The Braunwald criteria for unstable
angina (5), as well as the Unstable Angina Clinical Practice
Guidelines (6), suggest that patients with unstable angina
can be categorized into low, moderate and high-risk groups.
Clinical factors at initial presentation may help categorize
such patients and possibly determine the optimal manage-
ment for each (6–8). Preliminary data indicate that newer
therapies, such as Gp IIb/IIIa inhibitors and low-
molecular-weight heparin (3,9), are beneficial only in high
risk patients, but risk stratification has not been applied to
determine which patients should be treated with an early
invasive versus early conservative management strategy.
According to this concept of risk stratification to guide
management, some subgroups of patients with unstable
angina or NQMI might be more likely to benefit from early
invasive management, whereas others might not (10–14).
We risk-stratified patients with unstable angina or NQMI
on the basis of clinical data collected at presentation and
tested whether high risk subgroups differed in the effect of
an early invasive strategy.
METHODS
Patients. The analysis was based on data from patients
enrolled in the Thrombolysis In Myocardial Infarction
(TIMI) IIIB trial; its methods and participants have been
described in detail previously (1). Briefly, TIMI IIIB was a
randomized controlled trial of patients with unstable angina
or NQMI, designed to determine whether outcomes could
be improved with an early invasive management strategy
versus conservative (medical) management. Eligible patients
had experienced chest pain at rest in the prior 24 h lasting
$5 min but #6 h that was judged to be caused by cardiac
ischemia, as evidenced by several criteria: new electrocar-
diogram (ECG) evidence of ischemia in at least two
contiguous leads ($0.1 mV ST segment elevation lasting
,30 min, transient or persistent $0.1 mV ST segment
depression, or T-wave inversion during an episode of pain at
rest within the prior seven days), history of prior myocardial
infarction (MI), $70% stenosis on a previous coronary
arteriogram or a positive exercise thallium scintigram. Pa-
tients were excluded if they had any of the following: a
treatable cause of unstable angina, such as thyrotoxicosis; an
MI within the prior 21 days; a history of coronary arteriog-
raphy within 30 days; percutaneous transluminal coronary
angioplasty (PTCA) within six months or coronary artery
bypass grafting (CABG) at any time in the past.
The trial enrolled 1,473 patients, who were randomly
assigned to early conservative or early invasive therapy. The
patients were mostly white, middle-aged and men (Table 1).
Most had a history of angina, and one-third experienced
symptoms severe enough to place them in Canadian Car-
diovascular Society Class II or higher (angina with walking
stairs resulting in mild functional limitations or worse).
About a third of patients reported an MI $21 days before
enrollment. Cardiac risk factors were common. The out-
comes of interest included death or MI. All MIs were
reviewed and classified by the Central Classification Com-
mittee; a creatine kinase-MB fraction (CK-MB) exceeding
normal or, if no CK-MBs were available, a total CK greater
than twice normal was considered evidence of infarction (1).
In the group as a whole, the proportion of subjects who died
or experienced an MI by 42 and 365 days was similar
regardless of management assignment (1).
Management protocols. The conservative treatment pro-
tocol of TIMI IIIB included bed rest, oxygen, a beta-
adrenergic blocking agent (metoprolol 50 mg orally every
12 h), a calcium channel blocking agent (diltiazem 30 mg
orally every 6 h), a long-acting nitrate (isosorbide dinitrate
10 mg orally every 8 h), sublingual and/or intravenous
nitroglycerin, heparin and aspirin. Patients were continued
on anti-ischemic medicines after discharge. Patients in this
arm underwent cardiac catheterization and revascularization
only if indicated by evidence of ongoing ischemia despite
maximal medical therapy (see Outcomes section).
By contrast, patients randomized to the early invasive
strategy underwent cardiac catheterization, left ventricular
angiography and coronary arteriography 18 to 48 h after
randomization. Angiograms were reviewed immediately to
determine whether a culprit coronary artery lesion could be
identified; if so, revascularization by PTCA or CABG was
performed.
Patients were also randomized to tissue plasminogen
activator (t-PA) versus placebo. No effect of this treatment
was observed in the original trial findings.
Development of the risk score. The primary outcome of
interest used in developing the risk-stratifying score de-
scribed here was death or MI within 42 days of random-
ization. The rate of death or MI at 365 days was examined
as a secondary end point. The relationship of the candidate
variables with the primary end point was examined using
data for patients in both management arms of TIMI IIIB.
On the basis of the existing literature, we considered
several variables available at presentation that could predict
poor outcomes for patients with unstable angina and
NQMI. These included patient factors that could be easily
accessed at the bedside by physicians, including age, gender,
Abbreviations and Acronyms
CABG 5 coronary artery bypass grafting
CI 5 confidence interval
CK-MB 5 creatine kinase-MB fraction
CRP 5 C-reactive protein
cTnI 5 cardiac troponin I
ECG 5 electrocardiogram
Gp 5 glycoprotein
MI 5 myocardial infarction
NQMI 5 non–Q-wave myocardial infarction
OR 5 odds ratio
PTCA 5 percutaneous transluminal coronary
angioplasty
TIMI 5 Thrombolysis In Myocardial Infarction
t-PA 5 tissue plasminogen activator
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characteristics of prior angina, signs of congestive heart
failure, ECG abnormalities, CK-MB, cardiac troponin I
(cTnI) and C-reactive protein (CRP) (Table 2).
Age and gender have long been known to be important
predictors of death or MI (15–19). Several characteristics of
a patient’s angina portend poor outcomes, including epi-
sodes lasting .20 min, nocturnal episodes and an acceler-
ated pattern (20,21). Congestive heart failure is also asso-
ciated with a poor prognosis in these patients (6). ST
segment depression or elevation on the baseline ECG has
been found to predict subsequent acute MI and death
(18,22,23), as have serum markers such as CK-MB, cTnI
and CRP (9,18,24–31).
To determine whether to assess predictive factors as
continuous, ordinal or categorical variables, we examined
their relationships with the primary outcome, death or MI
at 42 days. Age was first examined as a continuous variable,
then in five-year increments and finally collapsed into
decades. In the original trial, patients were queried about
several aspects of their angina in the two months preceding
presentation, including the presence of episodes .20 min,
accelerated episodes of angina and any history of angina
with pain .20 min. We assessed the relationship between
these aspects of patients’ angina and rates of outcomes. An
ordinal scale (one point for each angina characteristic
present) predicted the outcome as well as did the individual
characteristics considered separately, and no one character-
istic was more predictive than another. Hence, angina was
considered “complicated” if any of the above characteristics
were present.
Congestive heart failure was considered present if an S3
or rales were heard on the initial physical examination. Of
the baseline ECG findings, only ST segment depression
$0.1 mV was significantly associated with the outcome of
interest. Cardiac troponin I was considered in several ways:
as a continuous variable; in deciles; and, based on prior work
(25), trichotomized at ,0.4 ng/ml, 0.4 to 3.99 and $4.0.
Each definition had a similar association with the outcome,
and the three-level definition was used in subsequent
analyses. We treated CK-MB in a similar fashion with
similar results; a variable dichotomized at 5 IU/ml per-
formed similarly to other definitions and was chosen for
further analyses. C-reactive protein testing was performed
according to recent protocols (32), and values ranged from
0.1 to 260.09 mg/dl. This variable was examined in a
continuous fashion, by deciles, and dichotomized at 1.55
mg/dl on the basis of prior work (29). The two-level CRP
variable performed as well as a continuous or ten-level
variable; because it would be easier to use at the bedside, we
used the dichotomous CRP for further analyses.
All categories and cut points were identified before any
Table 1. Baseline Patient Attributes and Outcomes in TIMI
IIIB by Management Arm
Early
Conservative
(n 5 733)
Early
Invasive
(n 5 740)
Patient attribute
Age, mean 6 SD (years) 59 6 10 59 6 10
Gender (% male) 66 66
Race (% white) 79 80
Comorbid conditions
Angina 87 84
Hypertension* 45 40
Hypercholesterolemia 19 21
Diabetes mellitus 15 14
Tobacco use 68 71
CCSC (column %)†
Class I 19 19
Class II 26 24
Class III 10 10
Class IV 5 5
History of MI 39 42
History of PTCA 13 14
S3 or rales at
presentation
2 1
Angina pattern in two
months prior to
presentation
Accelerated 34 34
Episodes .20 min 18 18
Episodes at rest 47 47
Nocturnal episodes 22 20
Electrocardiogram at
baseline
T-wave inversion 48 45
ST segment
depression
30 35
ST segment elevation 11 10
CK-MB, median (25th,
75th percentile)
2.8 (1.1, 9.3) 3.1 (1.2, 12.0)
Cardiac troponin I,
mean 6 SD*
1.28 6 3.85 2.19 6 6.47
C-reactive protein, mean
6 SD
7.12 6 17.99 6.29 6 12.14
Outcomes
Death by 42 days 2 2
MI by 42 days 6 6
Death by 365 days MI 4 4
MI by 365 days 9 8
*p , 0.05; †Does not add to 100% because not all patients reported angina. All figures
represent % with a given characteristic unless noted. Not all 1,473 patients had blood
test results available at baseline; 1,366 CK-MBs, 1,373 cardiac troponin, and 1,354
C-reactive protiens were included in these analyses. p-Values for normally distributed
continuous variables were calculated using a Student t test, and the Wilcoxon test was
used for non-normally distributed variables. For categorical variables, chi-squared
tests were used. CCSC 5 Canadian Cardiovascular Society Classification; CK-MB 5
creatine kinase-MB fraction; MI 5 myocardial infarction; PTCA 5 percutaneous
transluminal coronary angioplasty; SD 5 standard deviation; TIMI 5 Thrombolysis
In Myocardial Infarction.
Table 2. Candidate Predictive Factors
Predictive Factors
Supporting
References
Age (5,6,15,18)
Gender (15,18)
Angina pattern (5,6)
Congestive heart failure (5,6,16)
Electrocardiogram (18,22)
Cardiac serum markers
Creatine kinase-MB (18,24)
Cardiac troponin I (25,26,27,29)
C-reactive protein (28,29,30,31)
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assessment of outcomes, and in a manner designed to
enhance ease of use at the bedside.
Data analysis. To develop the risk-stratification rule, un-
adjusted logistic equations were first used to examine the
relationship of each of the predictive factors with the
primary outcome, death or MI within 42 days. These crude
relationships were assessed in the total TIMI IIIB popula-
tion. Predictive factors with p values #0.2 were considered
potential predictors of death or MI and were entered in a
multivariate model. Variables with p values .0.2 in these
adjusted models were removed. We chose this cut point
because the goal of our model was to develop a prediction
rule rather than to determine epidemiologic association.
The prediction rule was statistically validated by sampling
1,000 subgroups of patients from the cohort (bootstrap
procedure) to determine the internal consistency of the
factors determined on multivariate modeling. We compared
the predictive ability of the original and bootstrapped
multivariate models by examining the area under the re-
ceiver operating characteristic curves (C statistic) (33). The
odds ratios (ORs) derived from the final adjusted model
were used to define the weights for each predictor in the
risk-stratification rule.
We tested for the presence of confounding by study
hospital or assignment to the t-PA arm by examining the
changes in multivariate ORs of the original predictors using
a conditional logistic model (PROC PHREG in SAS); the
point estimates changed by ,7% and thus we did not
include study hospital or t-PA in the final model. Addi-
tionally, we assessed whether patient risk factors were
balanced within centers (design effect) by examining the
changes in standard errors in the conditional logistic mod-
els; the standard errors varied ,8%, suggesting an insignif-
icant design effect.
To facilitate such an approach at the bedside, a risk score
and risk categories were created. Variables with ORs from
1.01 to 1.5 were assigned 1 point, 1.51 to 2.0 were assigned
2 points, 2.01 to 2.5 were assigned 3 points and so on. We
summed the points to create five categories for risk-
stratification score: very low risk (0 to 2 points), low risk (3
to 4 points), moderate risk (5 to 6 points), high risk (7 to 8
points) and very high risk (9 to 10 points). The rates of
death or MI by 42 days in each risk category were then
calculated. This was done separately for the study sample as
a whole as well as for the patients in each randomly assigned
management group. A chi-square test of trend was per-
formed on these values. A multivariate model that included
an interaction term between treatment assignment (early
invasive vs. early conservative) and risk category as a
predictor of death or MI within 42 days was then created.
Finally, we assessed the association between risk category
and treatment assignment in relation to the secondary
outcome of death or MI within 365 days, using similar
models. Chi-square tests were performed to determine the
significance of differences between rates of outcomes in
individual risk categories for the two management strate-
gies.
The predictive ability of the risk score was also compared
with that of the full multivariate model by examining the C
statistic for each. We compared the observed proportion of
patients who died or had an MI to the expected rates using
the Hosmer-Lemeshow goodness-of-fit test (34). All anal-
yses were run using SAS Statistical Software (SAS Institute
Inc. SAS Statistical Software, Cary, North Carolina).
RESULTS
In unadjusted analyses examining the relationship between
potential predictive factors and death or MI within 42 days,
the following variables all had p values #0.2 and were
included in the adjusted models: older age, by decade; a
history of complicated angina; S3 or rales at presentation;
ST segment depression on the initial ECG; and a CK-MB
fraction .5 IU/ml (Table 3). However, CRP and cTnI had
p values .0.2 and were therefore not included in further
analyses. The variable indicating the presence of S3 or rales
had a p value .0.2 in adjusted models and was likewise
removed; all other variables remained in the model. The
ORs from the final model were used to determine the
predictive factor weights (Table 4), with a total possible
Table 3. Crude and Adjusted Relative Risk of Death or Myocardial Infarction by 42 Days
Potential Predictive Factor
Crude Relative Risk
OR (95% CI) p Value
Adjusted Relative Risk
OR (95% CI) p Value
Age, by decade 1.51 (1.3, 1.9) 0.0001 1.5 (1.2, 1.8) 0.0004
Gender, female 0.9 (0.7, 1.5) 0.9 — —
S3 or rales 3.4 (1.2, 9.2) 0.02 1.5 (0.3, 7.0) 0.6
ST segment depression 2.0 (1.4, 3.0) 0.0004 1.6 (1.1, 2.5) 0.03
Complicated angina 1.5 (1.0, 2.3) 0.03 1.8 (1.2, 2.8) 0.004
CK-MB, .5 IU/ml 1.4 (0.9, 2.0) 0.2 1.3 (0.9, 2.0) 0.2
CTnI, by category 1.1 (0.8, 1.5) 0.5 — —
CRP, by category 1.0 (0.9, 1.1) 0.3 — —
Only variables with p values #0.2 on unadjusted analyses were entered into multivariate analyses. See text for description of each
predictive factor. Age was categorized into ,50, 50 to 59, 60 to 69, and $70 years. ST segment depression $0.1 mV.
Complicated angina defined as rest, nocturnal, accelerated or prolonged episodes in two months prior to presentation. CTnI was
grouped into ,0.4, 0.4 to 3.99, and $4 ng/ml. CRP was dichotomized at 1.55 mg/dl. Adjustments were made in the
multivariate analyses for all variables with p values #0.2.
CI 5 confidence interval; CK-MB 5 creatine kinase-MB fraction; CRP 5 C-reactive protein; CTnI 5 cardiac troponin I;
OR 5 odds ratio.
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score of 10. As expected, the rate of death or MI by 42 days
rose significantly for patients with greater scores in progres-
sively higher risk categories, as did the rate of death or MI
within 365 days (both p values , 0.001) (Table 5).
Figure 1A presents the rates of death or MI within 42
days for patients in each risk category. Outcomes are
presented separately for those randomized to early conser-
vative versus early invasive therapy. Patients in the very low,
low and moderate risk groups (0 to 6 points) had similar
rates of death or MI at 42 days, irrespective of management
assignment (5% of 594 patients assigned to the conservative
management arm versus 6% of 601 patients assigned to the
early invasive strategy). However, in the high and very
high-risk groups, patients managed with early catheteriza-
tion had lower rates of death or MI than did similar patients
managed conservatively (19% in the conservatively managed
patients versus 12% in the invasively managed group; risk
difference 5 7%, 95% confidence interval [CI] 21% to
15%).
Overall, in the higher risk categories, patients treated
with conservative management had a higher rate of death or
MI than patients managed invasively. There was a 92%
adjusted increase in risk of death or MI by 42 days with each
higher category of risk score for patients randomized to the
conservative arm (95% CI, 67% to 116%). By contrast,
patients treated with the early invasive strategy had an
adjusted increase per category of only 31% (95% CI, 4% to
67%). The interaction effect on outcomes between risk score
and management assignment was significant (p 5 0.03).
Thus, as illustrated in Figure 1A, patients in the high or
very high risk categories had lower rates of death or MI by
42 days if treated invasively rather than conservatively; no
such benefit was seen in patients in the lower-risk catego-
ries.
The trend for the secondary outcome, death or MI by 365
days, was very similar to the primary endpoint findings (Fig.
1B). Patients in the high or very high risk categories had
fewer deaths or MIs if randomized to early invasive therapy,
whereas those in the very low, low and moderate risk groups
had similar rates of outcome regardless of management
assignment; however, the interaction between increments of
risk and management assignment did not reach statistical
significance at the 365-day point (p 5 0.3).
The risk score and full multivariate model both had
moderate predictive power; the C statistic for the final
multivariate model was 0.66; for the one-variable logistic
model with risk category, C 5 0.64 (95% CI 0.60 to 0.70).
The C statistic for the bootstrapped multivariate model was
0.65. The predicted outcomes of the risk score were not
significantly different from the observed outcomes
(Hosmer-Lemeshow goodness-of-fit p 5 0.4).
DISCUSSION
Unstable angina and NQMI are very common problems
throughout the industrialized world; in the U.S. alone, they
accounted for more than 1.4 million hospital admissions in
one recent year (35). However, controversy persists over the
optimal management strategy for this syndrome, particularly
since the advent of several new invasive clinical approaches.
Although some have speculated that high-risk patients are
most likely to benefit from an early invasive strategy
(6,10,11), this concept has remained controversial. Even in
trials that demonstrate overall benefit from invasive strate-
gies (3,4), it is not clear whether most or all of this benefit
is realized in a subset of the study population at highest risk
of poor outcome. The present analysis demonstrates that
baseline patient factors known to be markers of poor
prognosis, identified at the time of presentation, can be used
Table 4. Points Assigned to Each Risk Factor
Risk Factor Points†
ST segment depression $0.1 mV* 2
Accelerated angina in prior two months 2
CK-MB, .5 IU/ml 1
Age, years
,50 0
51–59 1
60–69 3
$70 5
Maximum score 10
*Electrocardiogram changes were required to be present in at least two contiguous
leads; †Scores were created from final multivariable model. Points were assigned as
follows: 1 point for odds ratio 5 1 to 1.5, 2 points for odds ratio 5 1.51 to 2.0, 3
points for odds ratio 5 2.01 to 2.5, 4 points for odds ratio 5 2.51 to 3.0, and 5 points
for odds ratio . 3.0. For increasing decades of age, odds ratios were calculated based
on the log of the odds ratio, such that for persons 60 to 69 years of age the odds ratio
was 2.25 (1.52) and for those $70 years the odds ratio was 3.38 (1.53).
CK-MB 5 creatine kinase-MB fraction.
Table 5. Risk of Death or MI by 42 and 365 days, by Risk Category
Risk Category (Score)
Death or MI by 42 days Death or MI by 365 days
Early Conservative Arm Early Invasive Arm Early Conservative Arm Early Invasive Arm
Patients With Outcome/
Total Patients %
Patients With Outcome/
Total Patients %
Patients With Outcome/
Total Patients %
Patients With Outcome/
Total Patients %
Very low (0–2) 5/181 3 8/173 5 10/181 6 12/173 7
Low (3–4) 11/223 5 16/223 7 21/223 9 20/223 9
Moderate (5–6) 15/190 8 12/205 6 24/190 13 20/205 10
High (7–8) 20/114 18 12/101 12 27/114 24 21/101 21
Very high (9–10) 6/25 24 5/38 13 7/25 28 6/38 16
p values from chi-square tests of trend ,0.001 for both end points when conservative and invasive arms combined.
MI 5 myocardial infarction.
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to target a group of patients with unstable angina or NQMI
who are most likely to benefit from an early invasive
management strategy. Older age, prior complicated angina,
ST segment depression, and CK-MB . 5 IU/ml were all
associated with a higher risk of death or MI at 42 days. A
score developed from these variables proved to be a useful
predictor of benefit from invasive management: patients in
the high or very high risk categories who were randomized
to the early invasive strategy had lower rates of adverse
outcomes than did similar-risk patients who were medically
treated. This finding was statistically significant for the
primary outcome, death or MI by 42 days, and there was a
similar trend for death or MI within 365 days.
This study demonstrates that the process of risk stratifi-
cation of patients with unstable angina or NQMI can
identify those who are most likely to benefit from an early
invasive strategy. These findings are consistent with a close
examination of the VANQWISH and FRISC II trials. In
the VANQWISH trial, patients with NQMI who were
treated with initial medical therapy had better outcomes
than those treated with early invasive management (2).
However, patients in VANQWISH entered the trial up to
72 h after presentation; thus, the patients with the most
severe coronary artery disease, who were most likely to
benefit from an early cardiac catheterization, might have not
been entered into the trial. The FRISC II trial investigators
enrolled only higher risk patients, that is, those with ST
segment deviation or elevated CK-MB (3). Hence, the
benefits of an early invasive management in FRISC II are
consistent with our results in the higher risk categories.
Figure 1. (A) Rates of death or myocardial infarction (MI) by 42 days. (B) Rates of death or MI by 365 days. Patients treated with conservative (medical)
management (black bars) had a significantly higher rate of death or MI by 42 days in increasing risk categories (92% adjusted increase per category, 95%
confidence interval, [CI] 67% to 116%) compared with patients treated with the early invasive strategy (white bars) (only 31% adjusted increase per category,
95% CI, 4% to 67%; p 5 0.03). Although the trend was similar for death or myocardial infarction by 365 days, the interaction between risk category and
management assignment did not reach statistical significance (p 5 0.3).
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Risk stratification. Preliminary studies indicate that only
high risk patients benefit from the administration of either
Gp IIb/IIIa inhibitors or low-molecular-weight heparin
(3,9), but prior studies have not addressed the use of risk
stratification to select an early invasive versus early conser-
vative management strategy—a choice with much larger
implications for both risk and cost. Early risk stratification
may be of value not only to select management strategy, but
also specific pharmacologic agents within a strategy.
For example, a patient aged 65 (3 out of a possible 5
points), with chest pain suspected of being unstable angina,
but no evidence for “complicated” angina (0 of 2 points), no
depression in the ST segment on the initial ECG (0 of 1
point) and no elevation in CK-MB (0 of 1 point) would
have a total score of 3. This patient would be categorized as
low risk and would not have had any benefit from an early
invasive approach. On the other hand, another 65-year-old
patient (3 of 5 points) with ST segment depression $0.1
mV (2 of 2 points) and nocturnal angina (“complicated”
angina) in two months before presentation (2 of 2 points),
but with a normal CK-MB (0 of 1 point) would have a total
score of 7. Seven points would put this patient in the
high-risk category, suggesting that an early invasive ap-
proach may provide a reduction in the risk of death or MI
by 42 days.
Cardiac troponin I and CRP were not significantly
associated with death or MI within 42 days in these
patients. Previously, Antman et al. (25) found that cTnI was
associated with death at 42 days using the same data. We
were able to reproduce this finding but did not find a similar
relationship when MI was added to the composite end
point. Although some researchers have found that CRP is
associated with death or MI, others have not (29–31,36,37).
We were not able to confirm this relationship. It is possible
that this reflects variations in laboratory assay techniques or
differences in patient populations.
Study limitations. Although the technology of coronary
intervention has evolved since this trial was conducted, the
approach presented provides a useful model for the evalua-
tion of any management strategy for unstable angina. The
randomized nature of the TIMI IIIB trial and its careful
follow-up make it well suited for the analyses we performed.
However, some important limitations of our findings must
be considered. First is the post-hoc nature of the subgroup
definition. Although not originally planned in the trial
protocol, our analyses were hypothesis-driven and grounded
in prior literature. Nonetheless, as a result, these findings
will need to be confirmed in other populations. Second, the
risk score was developed and tested in the same population.
However, development of the score pooled all patients, and
testing examined how well the score predicted outcomes in
each group separately; our finding is unlikely to result from
such an artifact. Furthermore, the predictive power of the
model did not decrease substantially on application of the
model to repeated samples of the study population using the
bootstrap method, confirming the validity of the risk-
stratification determination. Nonetheless, the risk score and
the implications noted above will require replication in
another population of patients with unstable angina or
NQMI. The purpose of our risk score was not to generate
a definitive risk-stratification process per se, but to allow us
to investigate the differential treatment effects of the two
management strategies based on accepted risk criteria.
Another important limitation of TIMI IIIB trial data is
the absence of use of Gp IIb/IIIa inhibitors and low-
molecular-weight heparin in the medical management strat-
egy, as well as coronary stents in those who underwent
cardiac catheterization; all patients did, however, receive
aspirin and heparin. Glycoprotein IIb/IIIa inhibitors, low-
molecular-weight heparin, and coronary stents are impor-
tant additions to the management of unstable angina, and
their use could influence the behavior of the risk-
stratification approach described here. As well, diltiazem
was part of the treatment protocol in the TIMI IIIB trial.
This is not part of standard care, but we do not believe it
influenced these results.
Implications. These findings have potentially important
implications for the management of patients with unstable
angina or NQMI. If confirmed in other populations, they
suggest that higher risk patients are more likely than lower
risk patients to benefit from early invasive management, as
they are likely to have better outcomes when treated
invasively than if treated with initial conservative therapy.
Of equal importance is the finding that the relatively larger
group of lower risk patients did not demonstrate a reduction
in rates of death or MI if randomized to early invasive
management. Even though TIMI IIIB was conducted
before the use of coronary stents and Gp IIb/IIIa inhibitors,
the underlying principle of risk stratification is likely to
apply in a wide variety of therapeutic settings. If replicated
in other settings and with other approaches (such as
coronary stents and Gp IIb/IIIa inhibitors), such a risk-
stratification scheme could provide a more evidence-based
approach to the management of the very large number of
patients with unstable angina and NQMI. It could also
result in a better allocation of invasive therapies to patients
most likely to benefit from them, sparing others the risk and
cost of such interventions.
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